Jhossmar Cristians Auza-SantiváñezJuan Pablo Jaldín-VasquezZuzel Salazar DuanyCarlos Sánchez EscalanteLuis Mariano Tecualt-GomezJosé Pedro Martínez Larrarte2026-03-222026-03-222021https://dialnet.unirioja.es/servlet/oaiart?codigo=8142265https://andeanlibrary.org/handle/123456789/71073For more than a century, convalescent plasma has been used as a passive immunization strategy to treat infectious diseases. It has been widely used to treat coronavirus disease under the assumption that such plasma contains potentially therapeutic antibodies against SARS-CoV-2. The objective of this article is to evaluate the clinical efficacy of convalescent plasma for the treatment of COVID-19. Evidence on its use in COVID-19 patients in recent weeks has been supported by more robust and consistent studies. Therefore, we consider that there is insufficient certainty and quality of evidence to recommend the use of convalescent plasma to prevent or treat outpatients or hospitalized patients with COVID-19. More research and solid arguments are needed before regulatory bodies recommend and include it in their protocols.esConvalescent plasmaCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusIntensive care medicineImmunizationAntibodyDiseasearticle